Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Regions face reduced federal research funding and shrinking venture capital for startups, though rankings stay consistent.

Pfizer Inc ( (PFE) ), Astellas Pharma ( (ALPMF) ), Astellas Pharma ( (ALPMY)) announced an update on their ongoing clinical study.

Bristol Myers Squibb has appointed Dr Cristian Massacesi as Executive Vice President, Chief Medical Officer and Head of ...

On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...